Literature DB >> 22210923

Differences between squamous cell carcinoma and adenocarcinoma of the lung: are adenocarcinoma and squamous cell carcinoma prognostically equal?

Akikazu Kawase1, Junji Yoshida, Genichiro Ishii, Masayuki Nakao, Keiju Aokage, Tomoyuki Hishida, Mitsuyo Nishimura, Kanji Nagai.   

Abstract

OBJECTIVE: We analyzed pulmonary squamous cell carcinoma and adenocarcinoma patient survival in our single institution database, to evaluate the relationship of histologic analysis to survival and tumor aggressiveness.
METHODS: We reviewed 1856 consecutive patients with surgically resected pulmonary squamous cell carcinoma or adenocarcinoma regarding their clinicopathologic characteristics, overall survival and recurrence-free proportion.
RESULTS: In squamous cell carcinoma patients, there were more elderly male smokers and more patients with T2-4 tumors, moderately/poorly differentiated tumors, lymph node metastasis or vascular invasion than in adenocarcinoma patients. In all patients and in pN0 patients, patients with squamous cell carcinoma showed significantly poorer overall survival than those with adenocarcinoma, but there were no statistically significant differences in the recurrence-free proportion between the two histologic types. There were statistically significantly more lung cancer-specific deaths in patients with adenocarcinoma than in patients with squamous cell carcinoma (P= 0.001).
CONCLUSIONS: There were no differences in the development of recurrence between squamous cell carcinoma and adenocarcinoma of the lung, but considerable differences in overall survival were observed between the two histologic types. According to the stage grouping strategy of the TNM Classification for Lung and Pleural Tumours, these two histologic types need to be staged differently. This survival difference, however, may reflect the difference in patient background rather than in biologic aggressiveness between the two histologic types.

Entities:  

Mesh:

Year:  2011        PMID: 22210923     DOI: 10.1093/jjco/hyr188

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  37 in total

1.  Discriminating lung adenocarcinoma from lung squamous cell carcinoma using respiration-induced tumor shape changes.

Authors:  Yi Lao; John David; Amin Mirhadi; Natasha Lepore; Howard Sandler; Yalin Wang; Richard Tuli; Wensha Yang
Journal:  Phys Med Biol       Date:  2018-11-07       Impact factor: 3.609

2.  Histological type predicts mediastinal metastasis and surgical outcome in resected cN1 non-small cell lung cancer.

Authors:  Tetsuya Mizuno; Takaaki Arimura; Hiroaki Kuroda; Noriaki Sakakura; Yasushi Yatabe; Yukinori Sakao
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-06-28

3.  Lung cancer histology classification from CT images based on radiomics and deep learning models.

Authors:  Panagiotis Marentakis; Pantelis Karaiskos; Vassilis Kouloulias; Nikolaos Kelekis; Stylianos Argentos; Nikolaos Oikonomopoulos; Constantinos Loukas
Journal:  Med Biol Eng Comput       Date:  2021-01-07       Impact factor: 2.602

4.  Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome.

Authors:  Richard Thomas; Yu-Hui Chen; Hiroto Hatabu; Raymond H Mak; Mizuki Nishino
Journal:  Lung Cancer       Date:  2020-04-30       Impact factor: 5.705

5.  Texture Analysis on [18F]FDG PET/CT in Non-Small-Cell Lung Cancer: Correlations Between PET Features, CT Features, and Histological Types.

Authors:  Francesco Bianconi; Isabella Palumbo; Mario Luca Fravolini; Rita Chiari; Matteo Minestrini; Luca Brunese; Barbara Palumbo
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

6.  Gene set selection via LASSO penalized regression (SLPR).

Authors:  H Robert Frost; Christopher I Amos
Journal:  Nucleic Acids Res       Date:  2017-07-07       Impact factor: 16.971

7.  Efficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer: A multi-center study of the Fukushima lung cancer association group of surgeons.

Authors:  Mitsunori Higuchi; Hironori Takagi; Yuki Owada; Takuya Inoue; Yuzuru Watanabe; Takumi Yamaura; Mitsuro Fukuhara; Satoshi Muto; Naoyuki Okabe; Yuki Matsumura; Takeo Hasegawa; Atsushi Yonechi; Jun Osugi; Mika Hoshino; Yutaka Shio; Koichi Fujiu; Ryuzo Kanno; Akio Ohishi; Hiroyuki Suzuki; Mitsukazu Gotoh
Journal:  Oncol Lett       Date:  2017-04-05       Impact factor: 2.967

8.  Comparisons of the clinicopathological features and survival outcomes between lung cancer patients with adenocarcinoma and squamous cell carcinoma.

Authors:  Takayuki Fukui; Tetsuo Taniguchi; Koji Kawaguchi; Koichi Fukumoto; Shota Nakamura; Yukinori Sakao; Kohei Yokoi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-05-30

9.  Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer.

Authors:  Garrett L Jensen; Chad Tang; Kenneth R Hess; Zhongxing Liao; Daniel R Gomez
Journal:  Clin Exp Metastasis       Date:  2017-07-25       Impact factor: 5.150

10.  The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer.

Authors:  Antonino Bruno; Chiara Focaccetti; Arianna Pagani; Andrea S Imperatori; Marco Spagnoletti; Nicola Rotolo; Anna Rita Cantelmo; Francesca Franzi; Carlo Capella; Guido Ferlazzo; Lorenzo Mortara; Adriana Albini; Douglas M Noonan
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.